Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of STS101 vs DHE in Healthy Adults
NCT05337254Phase 1Completed
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dihydroergotamine in migraine (5 arms). Primary endpoints: DHE Relative Bioavailability at 48 hours and DHE Comparative Bioavailability at 48 hours. Started Mar 2021; status: completed.
02
Drugs
dihydroergotamine
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05337254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05337254.